3,455 Shares of Waters Corporation $WAT Bought by First Nebraska Trust Co

First Nebraska Trust Co purchased a new position in shares of Waters Corporation (NYSE:WAT) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 3,455 shares of the medical instruments supplier’s stock, valued at approximately $1,518,000.

Several other large investors also recently bought and sold shares of the business. GRIMES & Co WEALTH MANAGEMENT LLC boosted its holdings in shares of Waters by 10.4% during the 3rd quarter. GRIMES & Co WEALTH MANAGEMENT LLC now owns 4,715 shares of the medical instruments supplier’s stock worth $2,072,000 after purchasing an additional 443 shares during the last quarter. BOCHK Asset Management Ltd purchased a new stake in shares of Waters in the third quarter valued at approximately $1,758,000. Next Level Wealth Planning LLC acquired a new stake in shares of Waters in the third quarter valued at approximately $29,000. Bank Julius Baer & Co. Ltd Zurich increased its holdings in shares of Waters by 1,510.8% in the third quarter. Bank Julius Baer & Co. Ltd Zurich now owns 198,542 shares of the medical instruments supplier’s stock valued at $87,377,000 after purchasing an additional 186,216 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. increased its holdings in shares of Waters by 3.0% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 220,471 shares of the medical instruments supplier’s stock valued at $96,873,000 after purchasing an additional 6,326 shares during the last quarter. Hedge funds and other institutional investors own 94.01% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Barclays boosted their price objective on Waters from $460.00 to $500.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 7th. HSBC raised their target price on Waters from $450.00 to $455.00 and gave the stock a “buy” rating in a research note on Tuesday, September 1st. Jefferies Financial Group lifted their price target on Waters from $450.00 to $455.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Robert W. Baird lifted their price target on Waters from $456.00 to $495.00 and gave the stock an “outperform” rating in a report on Thursday, October 8th. Finally, Morgan Stanley set a $430.00 price target on shares of Waters in a research report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and seven have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $457.50.

Insider Activity at Waters

In other news, Director Christopher Kuebler sold 3,626 shares of the business’s stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $397.94, for a total value of $1,442,930.44. Following the completion of the sale, the director directly owned 17,808 shares of the company’s stock, valued at approximately $7,086,515.52. The trade was a 16.92% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.31% of the company’s stock.

Trending Headlines about Waters

Here are the key news stories impacting Waters this week:

• Positive Sentiment: Q3 results topped estimates: Revenue was $1.767 billion, above expectations of about $1.75 billion, while adjusted EPS of $4.10 beat the $4.00 consensus and grew 21% year over year. Organic revenue increased 9% (10% in constant currency). Waters Q3 results
• Positive Sentiment: Higher outlook: Waters raised its 2026 revenue and earnings guidance after the beat. Its next-quarter revenue outlook also slightly exceeded expectations, supporting confidence in near-term momentum. Q3 beat and raised guidance
• Positive Sentiment: Promising 2027 framework: Management outlined a 29.2% adjusted operating-margin target and a path to high-single-digit growth, signaling expectations for continued expansion and profitability. 2027 growth framework
• Positive Sentiment: Strategic expansion in proteomics: Waters acquired MOBILion Systems, adding high-resolution ion-mobility technology to its mass-spectrometry portfolio. The deal is aimed at proteomics and biomarker research, including workflows designed for growing AI-driven lab demand. MOBILion acquisition announcement

Waters Stock Performance

Shares of WAT stock opened at $459.01 on Wednesday. Waters Corporation has a one year low of $282.77 and a one year high of $482.28. The firm’s 50 day moving average price is $432.11 and its 200-day moving average price is $371.16. The firm has a market cap of $45.10 billion, a P/E ratio of 114.47, a P/E/G ratio of 2.62 and a beta of 1.16. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.29 and a current ratio of 1.86.

Waters (NYSE:WAT) last issued its quarterly earnings results on Tuesday, November 3rd. The medical instruments supplier reported $4.10 earnings per share for the quarter, topping the consensus estimate of $4.00 by $0.10. The company had revenue of $1.77 billion for the quarter, compared to the consensus estimate of $1.75 billion. Waters had a return on equity of 11.27% and a net margin of 3.58%. Waters’s revenue was up 120.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.40 EPS. As a group, equities research analysts predict that Waters Corporation will post 14.56 EPS for the current year.

Waters Profile

Waters Corporation (NYSE:WAT) develops and manufactures analytical technologies used to measure, identify and characterize chemical and biological substances. Its customers include pharmaceutical and biotechnology companies, industrial manufacturers, academic and government laboratories, and organizations involved in food, environmental and clinical testing.

The company’s product portfolio includes high-performance liquid chromatography and ultra-performance liquid chromatography systems, mass spectrometers, chromatography columns and consumables, and laboratory software for data management and analysis.